Lotus Pharmaceuticals Competitors

Lotus Pharmaceuticals (OTCMKTS:LTUS) and OrganiGram (NASDAQ:OGI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Profitability

This table compares Lotus Pharmaceuticals and OrganiGram's net margins, return on equity and return on assets.

Risk and Volatility

Lotus Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, OrganiGram has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Lotus Pharmaceuticals and OrganiGram, as reported by MarketBeat.

OrganiGram has a consensus price target of $4.4113, indicating a potential upside of 75.05%. Given OrganiGram's higher possible upside, analysts plainly believe OrganiGram is more favorable than Lotus Pharmaceuticals.

Valuation & Earnings

This table compares Lotus Pharmaceuticals and OrganiGram's top-line revenue, earnings per share (EPS) and valuation.

Lotus Pharmaceuticals has higher earnings, but lower revenue than OrganiGram.

Institutional & Insider Ownership

10.8% of OrganiGram shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Profitability

This table compares Eagle Pharmaceuticals and Lotus Pharmaceuticals' net margins, return on equity and return on assets.

Institutional and Insider Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Eagle Pharmaceuticals and Lotus Pharmaceuticals, as provided by MarketBeat.com.

Eagle Pharmaceuticals presently has a consensus price target of $46.00, indicating a potential upside of 3.91%. Given Eagle Pharmaceuticals' higher possible upside, analysts clearly believe Eagle Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Valuation and Earnings

This table compares Eagle Pharmaceuticals and Lotus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Lotus Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Lotus Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

Lotus Pharmaceuticals (OTCMKTS:LTUS) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Institutional & Insider Ownership

64.3% of Relmada Therapeutics shares are held by institutional investors. 9.3% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Lotus Pharmaceuticals and Relmada Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Lotus Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Valuation and Earnings

This table compares Lotus Pharmaceuticals and Relmada Therapeutics' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Lotus Pharmaceuticals and Relmada Therapeutics, as provided by MarketBeat.com.

Relmada Therapeutics has a consensus target price of $63.3333, indicating a potential upside of 82.57%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Lotus Pharmaceuticals.

Summary

Relmada Therapeutics beats Lotus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Lotus Pharmaceuticals, as reported by MarketBeat.

Mirum Pharmaceuticals presently has a consensus target price of $40.1667, indicating a potential upside of 117.82%. Given Mirum Pharmaceuticals' higher probable upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Risk and Volatility

Mirum Pharmaceuticals has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Profitability

This table compares Mirum Pharmaceuticals and Lotus Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Mirum Pharmaceuticals and Lotus Pharmaceuticals' revenue, earnings per share and valuation.

Summary

Mirum Pharmaceuticals beats Lotus Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Lotus Pharmaceuticals (OTCMKTS:LTUS) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lotus Pharmaceuticals and SIGA Technologies, as reported by MarketBeat.com.

Profitability

This table compares Lotus Pharmaceuticals and SIGA Technologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Lotus Pharmaceuticals and SIGA Technologies' top-line revenue, earnings per share and valuation.

Lotus Pharmaceuticals has higher earnings, but lower revenue than SIGA Technologies.

Risk and Volatility

Lotus Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

29.3% of SIGA Technologies shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

SIGA Technologies beats Lotus Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lotus Pharmaceuticals (OTCMKTS:LTUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 7.1% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Crinetics Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Lotus Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Crinetics Pharmaceuticals and Lotus Pharmaceuticals, as provided by MarketBeat.

Crinetics Pharmaceuticals currently has a consensus price target of $35.00, suggesting a potential upside of 109.21%. Given Crinetics Pharmaceuticals' higher probable upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Lotus Pharmaceuticals.

Profitability

This table compares Crinetics Pharmaceuticals and Lotus Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Crinetics Pharmaceuticals and Lotus Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Lotus Pharmaceuticals has lower revenue, but higher earnings than Crinetics Pharmaceuticals.

Summary

Crinetics Pharmaceuticals beats Lotus Pharmaceuticals on 5 of the 8 factors compared between the two stocks.